Ranbaxy acquires 13 dermatology products from Bristol-Myers

These products have been present in the market for over 10 years and have been utilized in the treatment of acne, dermatitis, psoriasis, fungal infections and scabies. The US dermatology market value is estimated at $10 billion and has experienced growth of 10% per annum.

Ranbaxy already has a strong presence in the acne segment of the dermatology market with its best-selling product, Sotret Isotretinoin Capsules USP, for the treatment of severe recalcitrant nodular acne. Sotret is the largest selling brand among the isotretinoin brands with a market-share in excess of 36%, according to IMS.

The company says the 13 acquired products have significant synergy and represent an opportunity towards building a “dermatology business” with a predictable revenue stream.

The brands will be sold in the US market under the Ranbaxy Laboratories label. Ranbaxy believes that incremental sales from the 13 products can be generated through active promotion.

Venkat Krishnan, vice president and regional director for Ranbaxy in North America, said: “This business opportunity also creates a broader platform for the introduction of value added line extensions and additional brands as our involvement and commitment to dermatology expands. It underscores our strategy of pursuing inorganic growth opportunities to complement internal growth.”